PTC THERAPEUTICS, INC. - 10-Q Filing
PTC Therapeutics filed its Q1 2026 10-Q to provide updated financial and operational information, including details on equity securities, convertible debt instruments like the Convertible Senior Notes due September 15, 2026, and stock-based compensation plans. The filing also outlines revenue from products such as Upstaza, Kebilidi, Translarna, Sephience, Emflaza, and others across various regions.
Tickers: $PTCT